ONWARD announced the publication of a study in the journal, Nature, which found targeted electrical spinal cord stimulation stabilizes blood pressure in people with spinal cord injury (SCI).
by eazee-designstudio
ONWARD, announced the Company has successfully completed a $32M financing. The round was led by Invest-NL, the Dutch impact investor, and Olympic Investments, the private investment arm of the Onassis Foundation. Several additional new investors and all of ONWARD’s existing investors also participated in the financing, including leading medical technology investors LSP, INKEF Capital, Gimv, and Wellington Partners.
ONWARD, formerly known as GTX Medical, today announced the first patient has been enrolled in a pivotal trial evaluating the Company’s ARC TherapyTM.
Quanta announced that it has received 510(k) clearance from the US Food and Drug Administration (“FDA”) to market its small and simple, high performance hemodialysis system SC+.
PerkinElmer and Oxford Immunotec Global PLC are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec.
CARISMA Therapeutics, announced that Richard Morris has been appointed Chief Financial Officer (CFO).
CARISMA Therapeutics announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA’s total capital raised to nearly $109 million.
